Bioxon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bioxon

Property Description
Active ingredient Ceftriaxone
Form Powder for injection
Pharmacological class Third-generation cephalosporin, beta-lactam antibiotic
General purpose Anti-infective agent (Bactericidal)
Origin Synthetic compound

Bioxon is a widely used systemic anti-infective agent whose identity is rooted in the single active ingredient, Ceftriaxone. It is formally classified as a third-generation cephalosporin, which belongs to the larger family of beta-lactam antibiotics. This classification places it among the medicines clinically recognized for treating a number of severe bacterial infections.


What Type of Medicine is Bioxon, and What is its Composition?

The medicine is a synthetic compound, chemically manufactured as a single-component product with Ceftriaxone (International Nonproprietary Name) as the core active agent. As a third-generation cephalosporin, Ceftriaxone exhibits broad-spectrum activity, which signifies that its chemical structure is effective against a wide variety of susceptible bacteria. The drug is supplied primarily as a sterile powder for injection (typically the disodium salt), which is dissolved in a suitable aqueous base or solvent to create the final **solution for injection.


Bioxon’s Pharmaceutical Form and General Purpose

The core general purpose of Bioxon is to act as a definitive, bactericidal agent. The term bactericidal is critical to its function, signifying that the medicine is designed to actively kill the target bacteria rather than merely inhibiting their growth. This action is achieved by interfering with the synthesis of the bacterial cell wall.

This specialized form—a powder for injection intended for parenteral administration—ensures that the drug is delivered directly into the patient's system, bypassing the digestive processes. Ceftriaxone is an established standard for treating serious infections due to its reliable activity and stability. This rapid method of entry allows the drug to reach therapeutic concentrations quickly, which is essential for maximizing the efficacy of this broad-spectrum anti-infective agent.

Regulatory References

  1. NIH: Ceftriaxone Classification
  2. FDA Ceftriaxone Indications and Usage

What side effects are possible with Bioxon?

Possible Side Effects and Safety Information

The safety profile of Ceftriaxone (Bioxon) is structured around official regulatory classifications detailing known adverse reactions and safety constraints. The reported adverse effects are categorized by both frequency and the specific system or organ they affect.

Adverse Reaction Classifications

Common reactions (occurring in 1 to 10 out of 100 patients) often involve the Gastrointestinal System, such as diarrhea, and the Blood and Lymphatic System, including changes in blood counts like eosinophilia and leukopenia. Other common effects include rash and temporary elevations of liver enzymes (transaminases). Uncommon effects include nausea, vomiting, headache, and local reactions like phlebitis (vein inflammation) .

Documented Serious Safety Concerns

Official labeling emphasizes several severe, though less frequent, risks. These include serious hypersensitivity reactions such as anaphylaxis, which is a risk for all beta-lactam antibiotics. A critical gastrointestinal risk is Clostridioides difficile-associated diarrhea (CDAD), which can be potentially fatal. Furthermore, severe cases of immune-mediated hemolytic anemia have been reported.

Population-Specific Constraints

The most stringent safety constraints apply to specific patient groups. Ceftriaxone is strictly contraindicated for use in neonates receiving intravenous calcium-containing solutions due to the risk of life-threatening ceftriaxone-calcium precipitation in the lungs and kidneys. It is also contraindicated in neonates with hyperbilirubinemia due to displacement of bilirubin. Use is also contraindicated in anyone with a documented history of severe allergy to cephalosporins, penicillins, or other beta-lactam antibiotics.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that Bioxon (Ceftriaxone) overdose is primarily associated with high systemic concentrations of the drug, which can lead to documented adverse outcomes.

Overdose manifestations include the formation of ceftriaxone calcium salt precipitates in the gallbladder and urinary tract. While often asymptomatic, precipitation may present with symptoms such as pain, nausea, and vomiting.

Severe Outcomes and Required Action: High concentrations pose a risk of serious complications, including ureteric obstruction and post-renal acute renal failure (PARF). Serious neurological reactions, such as convulsions, are also reported, particularly in patients with pre-existing renal impairment. Immediate medical help must be sought if severe symptoms or organ injury are suspected.

Regulatory authorities mandate discontinuation of the drug and the provision of symptomatic and supportive treatment. The official label confirms that Ceftriaxone is not significantly removed by hemodialysis, meaning management is restricted to supportive care. Pediatric patients treated with doses ge 80 mg/kg/day are noted to have a higher risk of urinary tract precipitation.

Therapeutic Uses of Bioxon

What Bioxon Treats: Main Uses and Benefits

Bioxon (Ceftriaxone) is a third-generation cephalosporin, relevant for managing serious bacterial infections. Its core use is to address the underlying bacterial cause of the infection, which supports symptomatic relief for severe, acute manifestations.

The therapeutic use of Bioxon is aligned with official indications for addressing conditions presenting with systemic or localized discomfort across critical body systems. The medicine is commonly used across conditions presenting with heightened physiological stress, such as bacterial septicemia and meningitis, severe Community-Acquired Pneumonia, intra-abdominal infections, bone and joint infections, and pyelonephritis.

This medication is applied across therapeutic domains where additional symptomatic support is needed, often when symptoms create noticeable physiological strain. Its use contributes to easing the overall symptom load through supportive management of systemic symptoms, such as persistent high fever and rigors.

“This medicine is considered relevant in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.”


Quick Fact: Support for Systemic Symptoms

Bioxon is commonly used to help manage symptoms related to systemic imbalance, such as high fever and chills, by addressing the underlying bacterial infection.


Its application contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

This section summarizes the official eligibility and exclusion criteria for Bioxon (a representative macrolide antibiotic), as defined in authoritative governmental regulatory documents.


Contraindicated Populations (Must Not Use)

Individuals are strictly contraindicated and must not use Bioxon if they have a history of:

  • Known Hypersensitivity to Bioxon, any macrolide antibiotic, or any non-active components (excipients) in the formulation.
  • Cholestatic Jaundice/Hepatic Dysfunction previously associated with Bioxon use.
  • Documented Cardiac Arrhythmia including QT interval prolongation or ventricular rhythm disorders, such as Torsades de Pointes. This includes patients with uncorrected low potassium or magnesium levels (hypokalemia or hypomagnesemia).
  • Concomitant Use with certain restricted medications, including specified statins, ergot alkaloids, and other drugs that prolong the QT interval.

Restricted and Special Consideration Populations

Official labeling identifies populations where use is not recommended or requires special consideration:

  • Hepatic and Renal Impairment: Use is not recommended in patients with severe hepatic (liver) impairment. Use is restricted in the presence of severe renal (kidney) impairment, particularly when co-administered with certain interacting drugs.
  • Pregnancy and Lactation: Use during pregnancy is restricted, generally reserved for cases where no alternative is available and the need is clearly established. Use during lactation requires caution, as the drug is known to be excreted into breast milk.
  • Age: Use is generally permitted for pediatric patients and adolescents as specified. Older adults may require special monitoring due to increased sensitivity, though no absolute age-based prohibition exists.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Bioxon (Ceftriaxone) as specified in government regulatory information, focusing on required restrictions and monitoring.

Formally Contraindicated Combinations

Substance Constraint in Neonates (≤ 28 Days) Constraint in All Patients
Calcium-Containing IV Solutions Strictly Contraindicated (simultaneous or sequential administration) due to the risk of fatal precipitate formation. Must Not Be Mixed or administered simultaneously, even via different lines.

Documented Pharmacodynamic and Exposure Interactions

The co-administration of Bioxon with certain medicines requires specific monitoring based on regulatory warnings:

  • Oral Anticoagulants: Concomitant use with anti-vitamin K medicines, such as Warfarin, may increase the anti-vitamin K effect, resulting in a heightened risk of bleeding. Official labeling mandates the close monitoring of coagulation parameters.
  • Aminoglycosides and Chloramphenicol: Regulatory documents note potential for additive effects with Aminoglycosides (requiring monitoring) and in vitro antagonistic effects observed with Chloramphenicol.

Administration and Population-Specific Rules

  • Timing Separation: In patients older than 28 days, calcium-containing solutions may be administered sequentially only if the IV line is thoroughly flushed with a compatible fluid between the Bioxon infusion and the calcium infusion.
  • Lidocaine Diluent: Bioxon solutions reconstituted with Lidocaine must never be administered intravenously.
  • Population Note: Ceftriaxone is formally contraindicated in hyperbilirubinaemic neonates due to the risk of displacing bilirubin from serum albumin.

Mechanism of Action

How Bioxon Works

Molecular Targeting and Irreversible Inhibition

The core mechanism involves the drug acting as an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), which are essential bacterial enzymes. This molecular domain covers the drug's immediate interaction, where its beta-lactam structure covalently binds to and permanently disables the PBPs, thereby halting their enzymatic function of linking the peptidoglycan units required for cell wall synthesis.


Mechanistic Cascade to Bactericidal Effect

By stopping the final step of cell wall synthesis, the drug initiates a mechanistic cascade where the pathogen's structure is compromised, leading to osmotic instability. This failure activates the bacteria's own autolytic enzymes, culminating in the lysis (rupture) of the cell. This physiological outcome defines the drug's bactericidal effect and results in the death of the susceptible organism.


Constraints and Mechanism Limitations

The physiological action of this mechanism is biologically constrained by bacterial defenses. These limitations arise primarily from the bacterial production of beta-lactamase enzymes, which chemically destroy the drug before it reaches the target, or through the structural alteration of PBPs, which reduces the drug's binding affinity, thereby attenuating the inhibitory action.

Dosage and Administration Information

Instruction Map: How to use Bioxon — Official Administration Guidelines

This section describes the official administration guidelines for Bioxon (Ceftriaxone).


Administration Scope

Instruction Category Official Guideline
Route of Administration Administration is parenteral, primarily via Intravenous (IV) infusion, with the Intramuscular (IM) injection route available as an approved alternative.
Dosing Schedule (Adults) The standard adult daily dose is generally 1 g to 2 g. For the treatment of severe, life-threatening infections, the official dose may be increased up to a maximum of 4 g per day.
Preparation Requirements Bioxon is supplied as a sterile powder for injection and must be properly reconstituted using an officially specified diluent prior to administration.
Age-group administration rules Pediatric regimens are based on body weight, typically within a specific mg/kg/day range. No routine dose adjustment is needed for older adults or those with single-organ renal or hepatic impairment when receiving doses up to 2 g daily.
Special procedural conditions Co-administration with, or mixing in the same IV line as, any calcium-containing solutions is strictly prohibited due to the risk of precipitate formation. IV administration must be conducted as an intermittent infusion over a period of approximately 30 minutes.

Instruction Classifications (High-Level)

Classification Type Description
Administration method type Parenteral (IV and IM).
Frequency pattern Primarily Once Daily (q24h), with the option to divide the dose into Twice Daily (q12h) for conditions requiring higher sustained drug concentrations.
Course Duration Treatment duration is variable, typically spanning 4 to 14 days, and is often continued for at least 48 to 72 hours after the resolution of fever or other clinical signs of infection.

Connection to the overall use protocol

An established, specialized administration protocol dictates that Bioxon must be prepared from its powder form and delivered via the IV or IM route. This procedural framework defines the specific dose ranges and frequency (once or twice daily) required to achieve systemic presence. The use is constrained by the official incompatibility rule concerning calcium solutions and mandates a controlled infusion time, reinforcing its need for administration within a supervised clinical setting.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bioxon (Ceftriaxone)


Evidence for Use in Systemic Infections (Septicemia and Meningitis)

Research has explored Bioxon's use in settings involving severe infections that affect the entire body system, such as bacterial septicemia, and infections of the central nervous system, like meningitis. The research context for these uses is primarily defined by Regulatory Approval Data and its inclusion on major Essential Medicines Lists, which describe patterns related to a history of clinical use and data compilation. Studies explored whether the use of this medicine was associated with outcomes related to physiological strain, such as persistent high fever and chills. Findings show patterns related to Bioxon's evidence base being consistent with its recognized role in research scenarios involving these conditions. The evidence primarily focuses on the necessary short-term research period.


Evidence for Use in Site-Specific Infections (Pneumonia, Intra-abdominal, Bone/Joint, and Pyelonephritis)

Research has also examined the use of Bioxon for serious infections localized in specific areas, including severe community-acquired pneumonia, infections within the abdomen, infections in the bones and joints, and kidney infections like pyelonephritis. The evidence structure includes Pharmacological Studies and data describing its reliable activity and stability against a variety of susceptible bacteria. Studies monitored outcomes related to the change in the underlying bacterial cause of the infection in the affected area, as well as the outcomes related to systemic or functional imbalance that can accompany these infections.


What is Still Uncertain About Bioxon: Research Gaps and Limitations

While Bioxon has a well-established history and evidence base, the general research summaries reveal areas where data are still emerging. For many indications, follow-up durations were limited, focusing primarily on the acute phase, meaning there is limited information for long-term outcomes. Additionally, subgroup findings are uncertain regarding the extent of findings for all specific populations, such as different age ranges or those with certain coexisting health conditions. Comparative evidence is lacking in the general summaries provided, and evidence quality varies across studies based on their design and focus.

Key Studies & References WHO Prequalification Assessment Report (WHOPAR) - Ceftriaxone (as sodium) 1g Powder for Injection (Indications and Dosing)

Frequently Asked Questions (FAQ)

Common questions about Bioxon (FAQ)


Q: How long does the effect of one dose of Bioxon typically last?

A: Regulatory information reports that the elimination half-life of Bioxon in healthy adults generally falls between 5.8 and 8.7 hours. This half-life is a measure of how quickly the body processes the drug and is one of the factors considered by prescribers when determining the appropriate frequency of administration.


Q: Does Bioxon have a generic version available?

A: Yes, the active ingredient in Bioxon, Ceftriaxone, is widely available as a generic product in the United States and other regions. Generic products contain the same active ingredient and meet the same strict quality and effectiveness standards as the brand-name drug.


Q: Are there any long-term side effects associated with Bioxon use?

A: Regulatory labels primarily focus on documenting side effects that occur during the short-term course of treatment. The most stringent safety constraints are applied to the acute use phase, particularly concerning the risk of precipitation with calcium in newborns. Information on potential effects from very long-term use is typically more limited, as the drug is usually prescribed for short courses.


Q: Can Bioxon cause weight changes?

A: Weight change is not specifically listed as a common or uncommon adverse reaction in the official regulatory documentation for Bioxon. The documented common side effects typically relate to the gastrointestinal system and temporary blood count changes.


Q: What happens if I miss a dose of Bioxon?

A: Bioxon is typically administered under professional supervision in a clinical setting. Because of this, if an expected dose is missed, patients are advised to contact their healthcare provider or treatment team promptly to discuss rescheduling the dose.


Q: Do I need to take Bioxon with food?

A: No, Bioxon is administered via injection (intravenously or intramuscularly), which is known as the parenteral route. Since the drug bypasses the digestive system entirely, its absorption and effectiveness are not affected by food or the timing of meals.


Q: Is Bioxon safe for people with liver problems?

A: Official labeling states that for patients who have both severe liver (hepatic) and kidney (renal) impairment, the maximum daily dose should be restricted. A healthcare provider assesses the patient’s condition to determine if Bioxon is appropriate, especially when liver or kidney impairment is present.


Q: Can elderly patients take Bioxon?

A: Yes, Bioxon is used in elderly patients. Regulatory information indicates that no routine dose adjustment is necessary for older adults when receiving standard doses. However, older adults may require special monitoring due to potentially increased sensitivity to medications.


Q: Is Bioxon a controlled substance?

A: No, Ceftriaxone (Bioxon) is a prescription antibiotic medication. It is not classified as a controlled substance under the U.S. Drug Enforcement Administration (DEA) or similar international bodies.


Q: Is there a lot of research supporting the use of Bioxon?

A: Bioxon has a long-established history of clinical use and is included on the World Health Organization’s List of Essential Medicines. Its official approval for treating various severe bacterial infections reflects a large body of compiled evidence reviewed and accepted by major regulatory bodies.


Q: Have there been any major studies on Bioxon's effectiveness?

A: The drug’s regulatory approval is supported by clinical studies that demonstrated its safety and effectiveness for all its approved uses. This evidence includes trials specifically for serious infections like meningitis and septicemia.


Q: What kind of specialist usually prescribes Bioxon?

A: Given that Bioxon is approved to treat severe, systemic, and life-threatening infections, it is typically prescribed by physicians in hospital settings. These often include physicians and specialists who manage severe infections.


Q: Is it okay to crush or chew Bioxon tablets?

A: Bioxon is not available as an oral tablet. It is supplied as a sterile powder that must be dissolved into a solution for injection. Therefore, there is no tablet form to crush or chew.


Q: Where is Bioxon absorbed in the digestive system?

A: Bioxon is delivered via injection, bypassing the digestive system entirely to enter the bloodstream directly. Consequently, it is not absorbed through the stomach or intestines.


Q: Does Bioxon affect sleep patterns?

A: Official regulatory documents list less common adverse reactions that affect the nervous system, such as headache. Rarely, decreased consciousness or agitation has been reported, which could potentially be associated with changes in sleep patterns, though this is not a common side effect.


Q: What is the standard storage requirement for Bioxon solution after it is mixed?

A: After the Bioxon powder has been mixed with the appropriate liquid (reconstituted), the resulting solution has a very limited shelf-life. It must typically be used within 24 hours if stored in a refrigerator, or a much shorter period if kept at room temperature.


Q: Does Bioxon have potential interactions with common herbal supplements?

A: While regulatory information focuses on interactions with prescription medicines, it specifically advises caution when Bioxon is used with anti-vitamin K agents (like Warfarin), mandating close monitoring of blood coagulation. This suggests general caution is warranted with supplements that affect blood clotting.


Q: What are the signs that Bioxon is actually working for my condition?

A: Official guidance for treatment duration indicates that therapy is often continued for at least 48 to 72 hours after the resolution of fever or other clinical signs of infection. The disappearance of these core symptoms suggests that the medication is effectively controlling the bacterial infection.


Q: If I am taking Bioxon, can I still drive?

A: The drug label advises that the patient's ability to drive or operate machinery should be assessed, as side effects like dizziness (uncommon) or other nervous system reactions could occur.


Q: Are there specific times of day Bioxon should be taken?

A: The administration frequency is determined by the prescriber, typically once a day (q24h) or in some cases, divided into two doses per day (q12h). This frequency establishes the time interval between administrations, which is determined by the healthcare team.


Q: How long after taking Bioxon can I expect maximum concentration in my blood?

A: After an intravenous infusion, the maximum concentration in the blood is measured immediately after the 30-minute infusion is complete. Following an intramuscular injection, the maximum plasma concentration typically occurs approximately 2 to 3 hours after the dose.


Q: Does Bioxon affect fertility in men or women?

A: Nonclinical toxicology studies reviewed by regulatory bodies have shown no evidence that Bioxon impairs fertility or general reproductive performance in animal models.


Q: Is Bioxon a medication that requires regular monitoring?

A: Yes, when Bioxon is used alongside certain other medicines, specifically oral anticoagulants (blood thinners), official regulatory documents mandate the close monitoring of blood coagulation parameters.


Q: What should I do if I have an allergic reaction to Bioxon?

A: Official labels warn of the risk of severe hypersensitivity reactions, including anaphylaxis. If signs of an allergic reaction occur, immediate medical attention is required.


Q: Does the efficacy of Bioxon decrease over time?

A: The effectiveness of Bioxon may be reduced if the target bacteria develop resistance. This happens when the target bacteria develop mechanisms to inactivate or bypass the drug’s action.


Q: Is Bioxon safe for children or adolescents?

A: Bioxon is commonly used in pediatric patients. However, its use is strictly restricted in specific vulnerable groups, such as neonates with high bilirubin levels or those receiving intravenous calcium solutions, due to specific safety risks.

How should Bioxon be stored and disposed of?

The storage and disposal of Bioxon (Ceftriaxone) powder for injection must strictly comply with official regulatory labeling to ensure stability and safety.

Storage Requirements

Condition Type Requirement
Temperature Store the powder at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze the dry powder.
Protection Keep the product in the original container, tightly closed, and protected from light and moisture.
Stability After reconstitution, the solution has a limited shelf-life, which is typically up to 24 hours if refrigerated, or shorter if stored at room temperature.
Safety The medicine must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Bioxon should be disposed of through an approved drug take-back program or pharmaceutical collection site. If no take-back program is available, the medicine must be prepared for household trash disposal by mixing it with an undesirable substance, placed in a sealed bag, and discarded. The medicine must not be disposed of by pouring it down the sink or flushing it into the wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bioxon found in:

A-Z Index: